Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT04088396 |
| Consolidated Lead Sponsor | Eli Lilly and Company |
| Therapeutic Condition Cohort | Immunology, Rheumatology, and Dermatology |
| Clinical Trial Phase | Phase III |
| Overall Recruitment Status | ACTIVE NOT RECRUITING |
| Registered Enrollment | 58 participants (ESTIMATED) |
| Registered Start Date | 2020-02-12 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| UZ Gent | Ghent, Belgium | Open Hospital Dossier -> |
| Hospital de Clinicas de Porto Alegre | Porto Alegre, Brazil | Open Hospital Dossier -> |
| Vseobecna fakultni nemocnice v Praze | Prague, Czechia | Open Hospital Dossier -> |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Eli Lilly and Company across sibling Meru public-data platforms.
Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.